View Author
cancer prostate prostate cancer biopsy screening study value tumour patient volume score european randomized study treatment tumour volume antigen erspc result gleason european level round detection group table rotterdam diagnosis number disease lesion prostatectomy analysis velocity specimen randomized outcome stage cohort urology roobol screening round characteristic chapter prostate-speci fic antigen psa velocity surveillance tumor gleason score roobol mj threshold gland psa level interval control ficant progression prognostic value mortality signi population schr fh analyses sextant pca 3 model range expression follow-up schroder screening arm trial prostate-speci feature prognostic control arm schroder fh recurrence van der kwast screen prostate-specific predictor
10 Most Recent Publications
|
Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy
(Article)
Wolters, T. Montironi, R. Kwast, Th.H. van der Mazzucchelli, R. Scarpelli, M. Roobol, M.J. Bergh, R.C.N. van den Leeuwen, P.J. van Hoedemaeker, R.F. Leenders, G.J. van Schröder, F.H. |
2012-01-01
|
|
Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome
(Article)
Hoogland, A.M. Dahlman, A. Vissers, K.J. Wolters, T. Schröder, F.H. Roobol, M.J. Bjartell, A. Leenders, G.J. van |
2011-10-01
|
|
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial
(Article)
Wolters, T. Roobol, M.J. Leeuwen, P.J. van Bergh, R.C.N. van den Hoedemaeker, R.F. Leenders, G.J. van Schrder, F.H. Kwast, Th.H. van der |
2011-01-01
|
|
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: Reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100)
(Article)
Roobol, M.J. Schröder, F.H. Leenders, G.J. van Hessels, D. Bergh, R.C.N. van den Wolters, T. Leeuwen, P.J. van |
2010-12-01
|
|
Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic Test
(Article)
Roobol, M.J. Schröder, F.H. Leeuwen, P. van Wolters, T. Bergh, R.C.N. van den Leenders, G.J. van Hessels, D. |
2010-10-01
|
|
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
(Article)
Vickers, A.J. Wolters, T. Lilja, H. Savage, C.J. Cronin, A.M. O'Brien, M.F. Roobol, M.J. Aus, G. Scardino, P.T. Hugosson, J. Schröder, F.H. |
2010-09-01
|
|
The value of EZH2, p27kip1, BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy
(Article)
Wolters, T. Vissers, K.J. Bangma, C.H. Schröder, F.H. Leenders, G.J. van |
2010-07-01
|
|
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC
(Article)
Wolters, T. Roobol, M.J. Nelen, V. Tammela, T.L. Schröder, F.H. Steyerberg, E.W. Bergh, R.C.N. van den Bangma, C.H. Hugosson, J. Ciatto, S. Kwiatkowski, M. Villers, A. Lujan, M. |
2010-05-15
|
|
Should Pathologists Routinely Report Prostate Tumour Volume? The Prognostic Value of Tumour Volume in Prostate Cancer
(Article)
Wolters, T. Roobol, M.J. Leeuwen, P.J. van Bergh, R.C.N. van den Hoedemaeker, R.F. Leenders, G.J. van Schröder, F.H. Kwast, Th.H. van der |
2010-05-01
|
|
Improving Screening Strategies for Prostate Cancer
(Doctoral Thesis)
Wolters, T. |
2010-04-28
|
